Amgen wins orphan drug designation from FDA for Xgeva; Pfizer settles Parkinson's drug claims with some Australian plaintiffs;

@FiercePharma: Top-read pharma news this weekend: With Pfizer on the loose, traders worry Actavis-Allergan M&A saga isn't over yet. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. More | Follow @EricPFierce

@CarlyHFierce: ICYMI: Long-acting Copaxone to launch early next year in Europe, Teva says. Story | Follow @CarlyHFierce

> The FDA granted Amgen ($AMGN) orphan drug designation for Xgeva, a treatment for hypercalcemia of malignancy, a serious complication in patients with advanced cancer. Release

> Pfizer ($PFE) settled claims with 160 Australian plaintiffs who alleged that the company's drugs for Parkinson's disease caused gambling and hypersexual behavior. Story

> India's antitrust watchdogs cleared Sun Pharmaceutical's $3.2 billion deal to buy fellow Indian drugmaker Ranbaxy Laboratories pending product divestitures. Story

> Novo Nordisk ($NVO) revealed promising Phase III study data for its Novoeight treatment for hemophilia A at the 56th Annual Meeting of the American Society of Hematology. More

Medical Device News

@FierceMedDev: Physicians weigh in on ventricular assist devices for treating heart failure. Story | Follow @FierceMedDev

@EmilyWFierce: AstraZeneca scores a victory in pay-for-delay Nexium case. Article | Follow @EmilyWFierce

> J&J gains FDA clearance for rare pediatric spinal device. More

> National Cancer Institute backs startup's hazardous drug containment device. Story

> BlackBerry, NantHealth to launch HIPAA secure smartphone genome browser. News

Biotech News

@FierceBiotech: Merck splashes into antibiotics with $9.5B Cubist deal. Story | Follow @FierceBiotech

@JohnCFierce: Agios' AG-221 racks up more cancer remissions, setting the stage for a pivotal challenge. Article | Follow @JohnCFierce

@DamianFierce: Sun Pharma has a nuanced approach to Twitter. More | Follow @DamianFierce

> Six years and $8.8B later, Takeda is ditching the Millennium name. Item

> Merck's PD-1 star Keytruda shines at ASH, but lags behind Bristol-Myers' rival. Article

> Panel: How to understand the long biotech boom? Editor's Corner

CRO News

> WuXi moves to list a subsidiary on the Chinese market. More

> Recipharm cues job cuts as a long-time partner drops out. Report

> Catalent signs on to help Sellas get a repurposed drug to the finish line. Article

> INC Research lends its weight to trial site advocacy group. Item

> EU nations yank drugs over GVK data scandal. Story

Biotech IT News

> Hackers use Wall Street know-how to steal stock-moving biotech info. More

> Flatiron Health teams with Foundation Medicine to develop oncology platform. Report

> Ex-Pfizer SVP named CEO of BioClinica. Item

> Documents reveal FDA's use of computer forensics to uncover data falsification. Story

> 23andMe gets regulatory thumbs-up to sell DNA tests in U.K. Article

Animal Health News

> Kindred shares plummet as company nixes atopic dermatitis drug. Report

> Newly sequenced ferret genome reveals clues to human lung diseases. More

> Report: New FDA policy on animal antibiotics has loopholes. Item

> Eco Animal Health doubles pretax profit as it expands into North America. Story

> Nexvet partners with Virbac for ex-U.S. sales of canine osteoarthritis drug. Article

And Finally… Roche ($RHHBY) is close to selecting a prospective buyer for its campus in North Jersey, sources say. The Swiss drugmaker announced in 2012 that it would leave the site after 80 years and hopes to find a buyer by the end of 2015. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.